期刊文献+

A population study of fasting time and serum prostate-specific antigen (PSA) level 被引量:1

禁食时间和血清前列腺特异抗原(PSA)水平的人群研究
下载PDF
导出
摘要 Prostate cancer is one of the most common cancers in men. Traditional screening and diagnostic methods include digital rectal examinations (DREs), biopsies and serum prostate-specific antigen (PSA) tests, with the latter being the more popular. PSA is a biomarker for prostate cancer; however, it is highly sensitive to external factors as well as other prostate diseases. As such, the reliability of of the serum PSA level as a sole screening and diagnostic tool for prostate cancer is controversial. Recently, it has been shown that fasting extremes can affect concentrations of serum chemistry analytes, thus raising the question of whether or not fasting has an effect on the highly sensitive PSA biomarker. Patients testing for serum PSA levels are often concomitantly submitting to other tests that require fasting, subjecting certain patients to a fasting PSA level while others not. The objective of this study was to investigate whether this discrepancy in fasting state translates into an effect on serum PSA levels. Serum PSA levels and fasting time records for 157 276 men who underwent testing at Calgary Laboratory Services (CLS; Calgary, Alberta, Canada) between 01 January 2010 and 31 March 2013 were accessed. Linear regression models of mean PSA levels and fasting times revealed a statistically important relationship at certain fasting times. Applying a dynamic mathematical model to explore the clinical effect of fasting suggests minimal impact on serum PSA result interpretation. Thus, patients can be tested for serum PSA levels regardless of their fasting state. Prostate cancer is one of the most common cancers in men. Traditional screening and diagnostic methods include digital rectal examinations (DREs), biopsies and serum prostate-specific antigen (PSA) tests, with the latter being the more popular. PSA is a biomarker for prostate cancer; however, it is highly sensitive to external factors as well as other prostate diseases. As such, the reliability of of the serum PSA level as a sole screening and diagnostic tool for prostate cancer is controversial. Recently, it has been shown that fasting extremes can affect concentrations of serum chemistry analytes, thus raising the question of whether or not fasting has an effect on the highly sensitive PSA biomarker. Patients testing for serum PSA levels are often concomitantly submitting to other tests that require fasting, subjecting certain patients to a fasting PSA level while others not. The objective of this study was to investigate whether this discrepancy in fasting state translates into an effect on serum PSA levels. Serum PSA levels and fasting time records for 157 276 men who underwent testing at Calgary Laboratory Services (CLS; Calgary, Alberta, Canada) between 01 January 2010 and 31 March 2013 were accessed. Linear regression models of mean PSA levels and fasting times revealed a statistically important relationship at certain fasting times. Applying a dynamic mathematical model to explore the clinical effect of fasting suggests minimal impact on serum PSA result interpretation. Thus, patients can be tested for serum PSA levels regardless of their fasting state.
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2014年第5期740-744,I0009,I0010,共7页 亚洲男性学杂志(英文版)
关键词 diagnostic test FASTING prostate-specific antigen (PSA) diagnostic test fasting prostate-specific antigen (PSA)
  • 相关文献

参考文献30

  • 1Prostate Cancer. Available from: http:llwww.phac-aspc.gc.ca/cd-mc/cancer/prostate_ cancer-cancer_prostate-eng [Last accessed on 2013 Aug 22].
  • 2Canadian Cancer Statistics 2013. Available from: http://www.cancer.ca/en/ cancer-information/cancer- 101/canadian-cancer-statistics-pu blication/?region=ab [Last accessed on 2013 Aug 22].
  • 3Amling CL. Prostate-specific antigen and detection of prostate cancer: what have we learned and what should we recommend for screening? Curr Treat Options Oncol 2006; 7: 337-45.
  • 4Parekh D J, Ankerst DP, Troyer D, Srivastava S, Thompson I M. 8iomarkers for prostate cancer detection. J Uro12007; 178: 2252-9.
  • 5Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ2007; 176: 1853-8.
  • 6Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993; 119: 914-23.
  • 7Bunting PS, Goel V, Williams JI, Iscoe NA. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer. CMAJ 1999; 160: 70-5.
  • 8Levy I. Trends in incidence and mortality of prostate cancer in Canada. Chronic Dis Can 1995; 16: S2-6.
  • 9McGregor SE, Bryant HE, Brant RF, Corbett PJ. Prevalence of PSA testing and effect of clinical indications on patterns of PSA testing in a population-based sample of Alberta men. Chronic Dis Can 2002; 23: 111-9.
  • 10Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013; 1: CD004720.

同被引文献1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部